Inc280 治験
WebApr 10, 2015 · A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as … WebCapmatinib (INC280), a highly potent and selective inhibitor of the MET receptor, has shown in vitro and in vivo activity in cancer models with various types of MET activation. 19-21 In …
Inc280 治験
Did you know?
Web薬剤：INC280 (capmatinib) フェーズ：第II相; 進捗状況：募集終了; 試験種別：企業治験(グローバル) 1又は2ラインの全身治療歴があるEGFR野生型の進行性／転移性非小細胞肺が … Web臨床研究等提出・公開システム. 臨床研究・治験計画情報の詳細情報です。. (Japic) 治療歴のあるEGFR野生型ALK転座陰性の局所進行性／転移性非小細胞肺癌の成人患者を対象としてcapmatinib（INC280，経口MET阻害剤）及びspartalizumab（PDR001，PD-1阻害剤）の …
WebJun 10, 2016 · Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC The safety and scientific validity of this study is the responsibility of the study … WebMay 15, 2024 · Capmatinib (INC280, formerly INCB28060) is a highly selective and potent MET inhibitor with in vitro and in vivo activities against preclinical cancer models with MET activation . Capmatinib is being tested both as a single agent and in combination in multiple clinical trials that are guided by biomarker-based patient selection criteria.
WebMar 6, 2024 · INC280: 疾患名: 非小細胞肺がん: 薬効群名: その他の腫瘍用薬: 用法: INC280として1回400mgを1日2回、連日経口投与する。 試験の目的: 治療: 試験のフェーズ: 第Ⅱ … WebMay 25, 2024 · 9509 Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who were pretreated (cohort 4) or treatment (tx)-naïve (cohort 5b). Here, we report the efficacy and safety of capmatinib in pts with high-level MET-amplified (gene copy number …
WebMay 1, 2016 · 治験登録。 ich gcp。 ... met阻害剤を受けたことがあるmetエクソン14変異を有するnsclc患者におけるカプマチニブ（inc280）の研究 ...
Webこの試験では、inc280とブパルリシブの併用療法の安全性と用量を評価しました ..。治験登録。 ich gcp。 ... 臨性膠芽腫患者inc280とブプールシブ（bkm120）の安全性と有効性 再発性膠芽腫患者を対象としたinc280とブパリシブの併用療法の第ib / ii相多施設非盲検試験 how long ago were the dinosaurs killedWebJul 3, 2015 · The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important in ovarian cancer metastasis. Using in vitro and ex vivo models, we demonstrate that INC280 inhibits HGF-induced c-MET, and reduces downstream signalling. how long ago were adam and eve bornhttp://www.scrum-japan.ncc.go.jp/lc_scrum/trial/egfrnsclcc-metinc280ii/index.html how long ago were the dinosaurs hereWebNov 30, 2012 · This study is designed as a Phase II, single arm, open-label, multicenter study to evaluate the safety and efficacy of INC280 as first-line treatment in patients with advanced hepatocellular carcinoma (HCC) who are not eligible for or had disease progression after surgical or locoregional therapies, with c- MET dysregulation. how long a hen can lay eggsWeb臨床試験（治験）とは？ 実施中の臨床試験（治験）情報 研究・教育活動 ノバルティス ファーマ医学教育助成 Novartis Pharma Grants for Basic Research 2024 医学専門家団体 … how long ago were neanderthals aroundWebJul 19, 2024 · 概要 一般名 テポチニブ 商品名 テプミトコ 治験薬コード INC280 一般名英語表記 Tepotinib 商品名英語表記 TEPMETKO 種類 抗悪性腫瘍剤（MET阻害剤） 投与経路 … how long ago were fidget spinners popularWebNov 6, 2024 · Patients may also be assigned to EGF816 + INC280 or EGF816 + gefitinib in dose expansion. Efficacy assessments will be performed at baseline and every 2 cycles during treatment. Study Design. Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More … how long ago were glasses invented